New Zealand markets open in 1 hour 32 minutes

Aelis Farma S.A. (AELIS.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
11.300.00 (0.00%)
At close: 05:35PM CET

Aelis Farma S.A.

146 rue Léo Saignat
Neurocentre François Magendie
Bordeaux 33000
33 5 57 57 37 70

Full-time employees23

Key executives

NameTitlePayExercisedYear born
Dr. Pier Vincenzo Piazza M.D., Ph.D.CEO & DirectorN/AN/A1961
Ms. Valérie ScappaticciChief Financial OfficerN/AN/AN/A
Stephanie MonlezunChief Operating OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Aelis Farma S.A., a clinical-stage biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of unaddressed central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate in Phase 2b clinical trials for use in the treatment of the negative consequences of excessive cannabis use; and AEF0217, a drug candidate in Phase 1 clinical trials for use in the treatment of cognitive impairments due to a hyperactivity of the CB1 receptor, as well as cognitive deficits observed in Down syndrome. The company was incorporated in 2013 and is based in Bordeaux, France.

Corporate governance

Aelis Farma S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.